Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401927 | 1.00 | OPRD1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL12720564 | 0.93 | OPRD1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28130368 | 0.92 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL13313919 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL547920 | 0.91 | OPRD1 (0.70) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL14611969 | 0.91 | OPRD1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL542838 | 0.91 | OPRD1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL13313866 | 0.90 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL14516215 | 0.89 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16922134 | 0.89 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528804-B1 | CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND OPIOID AGONISTS AND/OR ANTAGONISTS | APIRX PHARMACEUTICAL USA LLC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3634377-B1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2021-07-21 | — | — | EP | claimed |
| EP-3169318-B1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LTD (IE) | 2020-04-01 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20230203053-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | XALUD THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | ISTANBUL GEDIK UNIVERSITESI | 2023-03-23 | — | — | US | disclosed |
| US-20230093302-A1 | A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | BAHCESEHIR UNIVERSITESI (TR) | 2023-03-23 | — | — | US | disclosed |
| US-11505556-B2 | Halogenated derivatives of morphinans and uses thereof | XALUD THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220008348-A1 | COMPOUND DELIVERY SYSTEMS AND METHODS OF PRODUCTION | GOLFETTO MICHAEL (US) | 2022-01-13 | — | — | US | disclosed |
| US-20210087202-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | XALUD THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3723749-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | Xalud Therapeutics, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118583-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | XALUD THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203053-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | OPRD1 26/4885OPRM1 4/4885OPRK1 13/4885 |
| US-11505556-B2 | Halogenated derivatives of morphinans and uses thereof | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | MAOB, MAOA, HTR2B | OPRD1 12/4885OPRM1 19/4885OPRK1 8/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRD1 4518/4885OPRM1 4810/4885OPRK1 2862/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | OPRD1 12/4885OPRM1 14/4885OPRK1 7/4885 |
| US-20230093302-A1 | A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | MAOB, MAOA, HTR1B | OPRD1 7/4885OPRM1 9/4885OPRK1 6/4885 |
| US-20210087202-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.